Latest Insider Transactions at Bellerophon Therapeutics, Inc. (BLPH)
This section provides a real-time view of insider transactions for Bellerophon Therapeutics, Inc. (BLPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Bellerophon Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Bellerophon Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 13
2023
|
Puissance Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,076,841
-100.0%
|
$0
$0.1 P/Share
|
|
Jun 07
2023
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
47,578
+14.02%
|
-
|
|
Jun 07
2023
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
134,421
-11.1%
|
$0
$0.83 P/Share
|
|
May 18
2023
|
Bobae Kim VP Reg. Affairs & Quality |
SELL
Open market or private sale
|
Direct |
9,455
-84.59%
|
$94,550
$10.0 P/Share
|
|
May 18
2023
|
Bobae Kim VP Reg. Affairs & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
1,288
+25.3%
|
$9,016
$7.43 P/Share
|
|
May 18
2023
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
560,000
-31.62%
|
$5,040,000
$9.46 P/Share
|
|
Feb 10
2023
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,000
+25.59%
|
-
|
|
Dec 09
2022
|
Peter Fernandes Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,985
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Peter Fernandes Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+50.0%
|
-
|
|
Dec 09
2022
|
Nicholas Laccona FINANCIAL OFFICER, (PFO & PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
5,530
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Nicholas Laccona FINANCIAL OFFICER, (PFO & PAO) |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+50.0%
|
-
|
|
Dec 09
2022
|
Parag Suresh Shah VP of Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
7,834
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Parag Suresh Shah VP of Business Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
25,500
+50.0%
|
-
|
|
Dec 09
2022
|
Martin Dekker Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,834
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Martin Dekker Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,500
+50.0%
|
-
|
|
Dec 31
2021
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,032
+19.58%
|
-
|
|
Jun 07
2021
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
8,189
+0.46%
|
$32,756
$4.0 P/Share
|
|
Apr 26
2021
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
609,231
+25.68%
|
$2,436,924
$4.0 P/Share
|
|
Mar 31
2021
|
Jonathan M Peacock |
BUY
Grant, award, or other acquisition
|
Direct |
15,308
+8.88%
|
-
|
|
Mar 18
2021
|
New Mountain Investments Ii, LLC |
SELL
Open market or private sale
|
Direct |
400,000
-39.63%
|
$2,000,000
$5.48 P/Share
|